Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

News SummaryMost relevantAll newsSector newsTweets 

US Judge Upholds Validity Of Merck's Vytorin Patent

share with twitter share with LinkedIn share with facebook
share via e-mail
04/28/2012 | 12:03am CEST
   By Peter Loftus 

A federal judge has upheld the validity of a U.S. patent covering Merck & Co.'s (>> Merck & Co., Inc.) Vytorin cholesterol-lowering drug, which could stave off competing generic copies for several years.

In an opinion released Friday, U.S. District Judge Jose Linares in federal court in Newark, N.J., said a patent for Vytorin was valid and enforceable.

Merck, based in Whitehouse Station, N.J., said in a recent regulatory filing it expects its U.S. exclusivity for Vytorin and a related drug, Zetia, to expire in April 2017.

Mylan Inc. (MYL) had applied for U.S. Food and Drug Administration approval to sell a generic version of Vytorin before its patent protection expired, arguing that the patent was invalid and unenforceable.

Schering-Plough, which was acquired by Merck in 2009, filed a patent-infringement lawsuit against Mylan in late 2009, seeking to block Mylan's product. A trial was held in December 2011, leading to Judge Linares's opinion Friday.

On a conference call with analysts Friday morning, Merck Chief Executive Kenneth Frazier said he was anticipating a favorable decision. "We believe this is a patent that is valid and enforceable," he said.

A Mylan spokeswoman couldn't immediately be reached.

Earlier Friday, Merck reported first-quarter Vytorin sales of $444 million and Zetia sales of $614 million.

Merck previously reached a settlement of patent litigation for Zetia with generics manufacturer Glenmark Pharmaceuticals. The pact will allow Glenmark to sell generic Zetia in December 2016, subject to final regulatory approval.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; [email protected]

Stocks mentioned in the article : Merck & Co., Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK & CO., INC.
04/22 MERCK : Announces New Phase 2 Data on Investigational Triple Combination Therapy..
04/21 MERCK : Marc J Bern & Partners LLP Files Lawsuits For A Hundred Individuals Agai..
04/21 MERCK : Real-World Observational Study in the U.S. Veterans Affairs System Evalu..
04/20 MERCK : New Findings from Merck & Company in the Area of Animal Science Describe..
04/20 MERCK : Recent Findings from Merck & Company Provides New Insights into Chromato..
04/20 MERCK : Report Summarizes Mass Spectrometry Study Findings from Merck & Company ..
04/20 MERCK : New Nuclear Magnetic Resonance Findings from Merck & Company Described (..
04/20 MERCK : New Findings in Essential Amino Acids Described from Merck & Company (La..
04/20 MERCK : Data on Pharmaceutical and Biomedical Analysis Reported by Researchers a..
04/20 MERCK : Investigators from Merck & Company Target Rabies Vaccines (Rationale and..
More news
Sector news : Pharmaceuticals - NEC
04/22DJNOVARTIS : Tests New Alzheimer's Drug on People Who Don't Have the Disease
04/21DJFDA OKs Samsung Bioepis's biosimilar version of J&J's Remicade
04/21 Teva's new asthma inhaler poses first competition for GSK's Advair
04/19DJSHIRE : Files 8K - Other Events
04/19DJFARON PHARMACEUTICALS OY : Appoints Two Non-Executive Directors
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
04/21 FDA approves Merck biosimilar for immune-disorder drug Renflexis
04/21 Merck Leads Rivals In Novel Drug Approvals
04/19 BIOLINERX : COMBAT Engagement
04/18 Healthcare Dogs See Medical Care Tops By Yield But Big Pharma Tops By Gains F..
Financials ($)
Sales 2017 39 677 M
EBIT 2017 13 557 M
Net income 2017 7 454 M
Debt 2017 3 973 M
Yield 2017 3,03%
P/E ratio 2017 21,64
P/E ratio 2018 18,25
EV / Sales 2017 4,38x
EV / Sales 2018 4,23x
Capitalization 169 673 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 68,9 $
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.5.13%169 673
JOHNSON & JOHNSON5.69%330 078
ROCHE HOLDING LTD.8.21%217 624
PFIZER INC.3.88%200 330
NOVARTIS AG-1.15%192 857
SANOFI8.35%114 121
More Results